These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9794881)

  • 1. Single dose of anti-D immunoglobulin for antenatal prophylaxis is smaller in the Netherlands than in the United Kingdom.
    van Dijk B
    BMJ; 1998 Oct; 317(7167):1253-4. PubMed ID: 9794881
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics of antenatal prophylaxis.
    Cairns JA
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():19-22. PubMed ID: 9863974
    [No Abstract]   [Full Text] [Related]  

  • 3. The prevention of Rh haemolytic disease of the fetus and newborn--general background.
    Contreras M
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():7-10. PubMed ID: 9863972
    [No Abstract]   [Full Text] [Related]  

  • 4. Routine antenatal anti-D prophylaxis: all change?
    Drug Ther Bull; 2015 Oct; 53(10):109. PubMed ID: 26449365
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing RhD haemolytic disease of the newborn. Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis.
    Lee D
    BMJ; 1998 May; 316(7144):1611. PubMed ID: 9596614
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prenatal immunoglobulin prevention in Rh(D)-negative nonsensitized pregnant women].
    Katsulov A
    Akush Ginekol (Sofiia); 1997; 36(2):1-2. PubMed ID: 9471891
    [No Abstract]   [Full Text] [Related]  

  • 7. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
    Chaffe B; Ford J; Bills V
    Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antenatal anti-D prophylaxis.
    Vick S; Cairns J; Urbaniak S; Whitfield C; Raafat A
    Health Econ; 1996; 5(4):319-28. PubMed ID: 8880168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
    Kumpel BM
    Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
    [No Abstract]   [Full Text] [Related]  

  • 10. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn.
    Qureshi H; Massey E; Kirwan D; Davies T; Robson S; White J; Jones J; Allard S;
    Transfus Med; 2014 Feb; 24(1):8-20. PubMed ID: 25121158
    [No Abstract]   [Full Text] [Related]  

  • 11. Antenatal anti-D immunoglobulin.
    Lancet; 1983 Sep; 2(8352):734. PubMed ID: 6136859
    [No Abstract]   [Full Text] [Related]  

  • 12. Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units.
    Harkness M; Freer Y; Prescott RJ; Warner P
    Transfus Med; 2008 Oct; 18(5):292-5. PubMed ID: 18937736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing RhD haemolytic disease of the newborn.
    van Dijk B
    BMJ; 1997 Dec; 315(7121):1480-1. PubMed ID: 9420481
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of immunoprophylaxis with anti-D immunoglobin.
    Engelfriet CP; Reesink HW; Judd WJ; Ulander VM; Kuosmanen M; Koskinen S; Rouger P; Morelati F; Tantalo V; Fujii T; de Haas M; van der Schoot CE; Overbeeke M; Koelewijn J; Bonsel G; Vrijkotte T; Zupańska B; Martin-Vega C; Parra Lopez R; de Silva M; Contreras M; Panzer S; Ulm B; Mayr WR
    Vox Sang; 2003 Nov; 85(4):328-37. PubMed ID: 14633261
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists.
    Hartwell EA
    Am J Clin Pathol; 1998 Sep; 110(3):281-92. PubMed ID: 9728602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus Conference on Anti-D Prophylaxis. Edinburgh, United Kingdom, 8-9 April 1997. Papers and abstracts.
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():iv, 1-44. PubMed ID: 10328662
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of hemolytic disease of the fetus and the newborn: it is necessary to act].
    Mannessier L; Alie-Daram S; Roubinet F; Valat AS; Depoortère MH; Fournié A; Puech F
    J Gynecol Obstet Biol Reprod (Paris); 2000 Sep; 29(5):441-4. PubMed ID: 11011272
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of anti-D in an accident and emergency department.
    Huggon AM; Watson DP
    Arch Emerg Med; 1993 Dec; 10(4):306-9. PubMed ID: 8110321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing RhD haemolytic disease of the newborn. Services should be centralised for pregnancies affected by RhD haemolytic disease.
    Craig JS; McClure BG; Tubman TR
    BMJ; 1998 May; 316(7144):1611. PubMed ID: 9616034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.